Argus® II Retinal Prosthesis System Post-Market Surveillance Study

Inclusion Criteria: Adults, age 25 year or older * with severe to profound outer retinal degeneration (not including Age-related Macular Degeneration) * Have some residual light perception. If no residual light perception remains, the retina must be able to respond to electrical stimulation; * Have previous history of useful form vision * Have consented to participate in the study * Had an Argus II Retinal Prosthesis surgically implanted 14 days (± 7 days) prior to enrollment (at Baseline Visit) in the study * At the time of the Baseline Visit, do not suffer from non-ophthalmic serious adverse events (e.g. coma, myocardial infarction, etc.). Exclusion Criteria: * Ocular diseases or conditions that could prevent Argus II from working (e.g. optic nerve disease, central retinal artery or vein occlusion, history of retinal detachment, trauma, severe strabismus, etc.) * Ocular structures or conditions that could prevent the successful implantation of the Argus II Implant or adequate healing from surgery (e.g. extremely thin conjunctiva; axial length \<20.5 mm or \> 26 mm; corneal ulcers; choroidal neovascularization in the area of the intended tack location, etc.) * Ocular diseases or conditions (other than cataracts) that prevent adequate visualization of the inner structures of the eye (e.g. corneal opacity) * Pre-disposition to eye rubbing * Any disease or condition that prevents understanding or communication of informed consent, study demands, and testing protocols, including: * cognitive decline including diagnosed forms of dementia and/or progressive neurologic disease, * psychiatric disease including diagnosed forms of depression; * does not speak a principal language associated with the region, and * deafness or selective frequency hearing loss that prevents hearing device alarms and alerts * Participants who are pregnant or wish to become pregnant during the course of the study * Participation in another investigational drug or device study that may conflict with the objectives, follow-up or testing of this study; * Conditions likely to limit life to less than 1 year from the time of inclusion.